FMR LLC reports 193,014 shares (0.4%) in Soleno Therapeutics

FMR LLC filed an amendment to a Schedule 13G/A reporting beneficial ownership of 193,013.61 shares of Soleno Therapeutics common stock, representing 0.4% of the class as of 04/30/2026.

Rhea-AI Filing Summary

FMR LLC filed an amendment to a Schedule 13G/A reporting beneficial ownership of 193,013.61 shares of Soleno Therapeutics common stock, representing 0.4% of the class as of 04/30/2026. The filing states sole dispositive power over 193,013.61 shares and no shared voting or dispositive power. Abigail P. Johnson is listed with dispositive power consistent with FMR's filing. The amendment is signed under a power of attorney and references Exhibit 99 for a 13d-1(k)(1) agreement.

Insights

Institutional Ownership Analyst

Large investment manager reports a small, passive stake in Soleno Therapeutics.

FMR LLC reports ownership of 193,013.61 shares (0.4%) as of 04/30/2026, with sole dispositive authority. The filing is an amendment to a Schedule 13G/A and indicates passive ownership classification consistent with 13G treatment rather than active 13D status.

Cash‑flow treatment or trading intent is not stated; the filing references an exhibit for an agreement. Subsequent filings or the exhibit may provide details about any underlying subsidiary or allocation across funds.

Key Figures

Beneficial ownership: 193,013.61 shares Percent of class: 0.4% Sole voting power: 192,655 shares +1 more

4 metrics

Beneficial ownership 193,013.61 shares Amount beneficially owned as reported

Percent of class 0.4% Percent of common stock as reported, as of 04/30/2026

Sole voting power 192,655 shares Sole voting power reported on cover page

Sole dispositive power 193,013.61 shares Sole power to dispose as reported

Key Terms

Schedule 13G/A, beneficially owned, dispositive power, 13d-1(k)(1) agreement

4 terms

Schedule 13G/A regulatory

"Amendment to Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: 193013.61"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

dispositive power regulatory

"Sole Dispositive Power 193,013.61"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

13d-1(k)(1) agreement regulatory

"Please see Exhibit 99 for 13d-1(k)(1) agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in Soleno Therapeutics (SLNO)?

FMR LLC reports beneficial ownership of 193,013.61 shares, equal to 0.4% of the common stock as of 04/30/2026. This amount reflects sole dispositive power of 193,013.61 shares as stated in the amendment.

Does FMR LLC report voting control over SLNO shares?

The amendment shows sole voting power of 192,655 shares and sole dispositive power of 193,013.61 shares. Shared voting and dispositive powers are reported as 0.00 in the filing's cover-page entries.

Is this a passive 13G filing or an active 13D for SLNO?

The document is an amendment to a Schedule 13G/A, indicating passive investor status under 13G rules. The filing does not convert to 13D language or assert active control in the provided excerpt.

Who signed the amendment for FMR LLC and Abigail P. Johnson?

The amendment is signed by Richard Bourgelas as duly authorized under a power of attorney dated April 13, 2026, for both FMR LLC and Abigail P. Johnson, with signature dates of 05/06/2026.

Where can I find more details about ownership allocation or subsidiary involvement?

The filing references Exhibit 99 for a 13d-1(k)(1) agreement and an exhibit describing any relevant subsidiary. Review Exhibit 99 or subsequent filings for allocation or subsidiary identification details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 10:32 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

SOLENO THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

834203309

(CUSIP Number)

04/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 834203309

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 192,655.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 193,013.61
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

193,013.61

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 834203309

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 193,013.61
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

193,013.61

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SOLENO THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 100 MARINE PARKWAY,SUITE 400,REDWOOD CITY,CA,US,94065
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 834203309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 193013.61
(b)	Percent of class: 0.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 193013.61
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of SOLENO THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of SOLENO THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/06/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/06/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.